廣告
香港股市 已收市
  • 恒指

    22,113.51
    -330.22 (-1.47%)
     
  • 國指

    7,914.16
    -127.11 (-1.58%)
     
  • 上證綜指

    3,336.50
    +248.97 (+8.06%)
     
  • 道指

    41,931.26
    -265.26 (-0.63%)
     
  • 標普 500

    5,688.26
    -21.28 (-0.37%)
     
  • 納指

    17,863.99
    -61.13 (-0.34%)
     
  • Vix指數

    20.45
    +1.55 (+8.24%)
     
  • 富時100

    8,263.72
    -27.14 (-0.33%)
     
  • 紐約期油

    72.99
    +2.89 (+4.12%)
     
  • 金價

    2,670.10
    +0.40 (+0.01%)
     
  • 美元

    7.7656
    +0.0030 (+0.04%)
     
  • 人民幣

    0.9030
    -0.0002 (-0.02%)
     
  • 日圓

    0.0527
    -0.0001 (-0.23%)
     
  • 歐元

    8.5526
    -0.0219 (-0.26%)
     
  • Bitcoin

    60,310.13
    -1,167.64 (-1.90%)
     
  • XRP USD

    0.52
    -0.06 (-10.73%)
     

FDA Approves Updated COVID Vaccines From Pfizer And Moderna, But Leaves Out Novavax's Shot

FDA Approves Updated COVID Vaccines From Pfizer And Moderna, But Leaves Out Novavax's Shot
FDA Approves Updated COVID Vaccines From Pfizer And Moderna, But Leaves Out Novavax's Shot

Thursday, the FDA granted emergency use authorization (EUA) for updated mRNA COVID-19 vaccines (2024-2025 formula) to include a monovalent (single) component that corresponds to the Omicron variant KP.2 strain of SARS-CoV-2.

The approval comes for the updated vaccines from Moderna Inc (NASDAQ:MRNA) and Pfizer Inc (NYSE:PFE) / BioNTech SE (NASDAQ:BNTX).

The mRNA COVID-19 vaccines have been updated with this formula to more closely target currently circulating variants and provide better protection against serious consequences of COVID-19, including hospitalization and death.

Also Read: Struggling COVID-19 Vaccines From AstraZeneca, BioNTech/Pfizer, Moderna Cut Incidence Of Arterial Thromboses That Cause Heart Attacks, Strokes, British Study Shows.

In early June, the FDA advised manufacturers of licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 formula) should be monovalent JN.1 vaccines.

Based on the further evolution of SARS-CoV-2 and a rise in cases of COVID-19, the agency subsequently determined and advised manufacturers that the preferred JN.1-lineage for the COVID-19 vaccines (2024-2025 formula) is the KP.2 strain, if feasible.

The updated mRNA COVID-19 vaccines include Comirnaty and Spikevax, both of which are approved for individuals 12 years of age and older, and the Moderna COVID-19 Vaccine and Pfizer-BioNTech COVID-19 Vaccine, both of which are authorized for emergency use for individuals six months through 11 years of age.

  • Unvaccinated individuals six months through 4 years of age are eligible to receive three doses of the Pfizer-BioNTech COVID-19 Vaccine or two doses of the updated Moderna COVID-19 Vaccine.

  • Individuals six months through 4 years of age who have previously been vaccinated against COVID-19 are eligible to receive one or two doses of Moderna or Pfizer-BioNTech COVID-19 vaccines.

  • Individuals 5 through 11 years of age, regardless of previous vaccination, are eligible to receive a single dose of the updated, authorized Moderna or Pfizer-BioNTech COVID-19 vaccines; if previously vaccinated, the dose is administered at least 2 months after the last dose of any COVID-19 vaccine.

  • Individuals 12 and older can receive a single dose of Comirnaty or Spikevax.

  • Additional doses are authorized for certain immunocompromised individuals ages 6 months through 11 years, as described in vaccine fact sheets.

The FDA assessed manufacturing and nonclinical data to support the change to include the 2024-2025 formula in the mRNA COVID-19 vaccines.

Moderna said the Spikevax 2024-2025 formula is expected to be available across the U.S. in the days immediately following approval.

Pfizer also said shipping will begin immediately.

Novavax Inc’s (NASDAQ:NVAX) COVID-19 vaccine was left out in today’s approval. Earlier, the company mentioned that it anticipates commercial delivery of the protein-based vaccine in the U.S. in September, pending authorization.

Price Action: PFE stock is down 1.18% at $28.69, BNTX stock is down 0.85% at $88.23, MRNA stock is down 5.08% at $82.25, and NVAX stock is down 5.72% at $12.20 at last check Thursday.

Read Next:

Photo via Wikimedia Commons

"ACTIVE INVESTORS' SECRET WEAPON" Supercharge Your Stock Market Game with the #1 "news & everything else" trading tool: Benzinga Pro - Click here to start Your 14-Day Trial Now!

Get the latest stock analysis from Benzinga?

This article FDA Approves Updated COVID Vaccines From Pfizer And Moderna, But Leaves Out Novavax's Shot originally appeared on Benzinga.com

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.